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ABSTRACT
Objective Previous studies have shown that ulcerative
colitis (UC) is associated with the presence of lamina
propria non-invariant (Type II) NKT cells producing IL-13
and mediating epithelial cell cytotoxicity. Here we sought
to deﬁne the antigen(s) stimulating the NKT cells and to
quantitate these cells in the UC lamina propria.
Design Detection of Type II NKT cells in UC lamina
propria mononuclear cells (LPMC) with lyso-sulfatide
loaded tetramer and quantum dot-based ﬂow cytometry
and staining. Culture of UC LPMCs with lyso-sulfatide
glycolipid to determine sulfatide induction of epithelial
cell cytotoxicity, IL-13 production and IL-13Rα2
expression. Blinded quantum dot-based phenotypic
analysis to assess UC LPMC expression of IL-13Rα2,
CD161 and IL-13.
Results Approximately 36% of UC LPMC were lyso-
sulfatide tetramer positive, whereas few, if any, control
LPMCs were positive. When tested, the positive cells
were also CD3 and IL-13Rα2 positive. Culture of UC
LPMC with lyso-sulfatide glycolipid showed that sulfatide
stimulates UC LPMC production of IL-13 and induces UC
CD161 LPMC-mediated cytotoxicity of activated
epithelial cells; additionally, lyso-sulfatide induces
enhanced expression of IL-13Rα2. Finally, blinded
phenotypic analysis of UC LP MC using multicolour
quantum dot-staining technology showed that
approximately 60% of the LPMC bear both IL-13Rα2
and CD161 and most of these cells also produce IL-13.
Conclusions These studies show that UC lamina
propria is replete with Type II NKT cells responsive to
lyso-sulfatide glycolipid and bearing IL-13Rα2. Since
lyso-sulfatide is a self-antigen, these data suggest that
an autoimmune response is involved in UC pathogenesis.
INTRODUCTION
Previous studies of a murine model of ulcerative
colitis (UC), oxazolone-colitis, as well as human UC
have provided evidence that these forms of intestinal
inﬂammation are marked by the presence of lamina
propria CD4 T cells that by several criteria are Type
II (non-invariant) NKT cells. Moreover, these
studies showed that upon stimulation, these NKT
cells produce IL-13 and exhibit cytotoxicity for epi-
thelial cells that is augmented by IL-13.1–3 While
these previous studies suggested that NKT cells play
an important pathogenic role in UC, they did not
address two important questions. First, they did not
deﬁne a glycolipid antigen responsible for TCR
stimulation of the NKT cells, and for thus initiating
or maintaining the UC inﬂammatory process.
Second, they did not identify an NKT cell surface
marker that could be used to quantitatively assess or
functionally evaluate these NKT cells in the lamina
propria of patients with UC.
Signiﬁcance of this study
What is already known on this subject?
▸ A murine model of ulcerative colitis (UC),
oxazolone colitis, as well as human UC, are
marked by the presence of CD4 NKT cells; in
UC, these cells are Type II NKT cells that are
non-invariant.
▸ Upon activation, the NKT cells secrete large
amounts of IL-13, a cytokine that is both
cytotoxic for epithelial cells, and that augments
NKT cell cytotoxicity for epithelial cells.
What are the new ﬁndings?
▸ The UC lamina propria is populated by a large
number of Type II NKT cells recognised by their
ability to bind lyso-sulfatide glycolipid-loaded
CD1d-tetramer.
▸ Lyso-sulfatide glycolipid stimulates UC lamina
propria NKT cells to produce IL-13, exhibit
increased epithelial cell cytotoxicity and display
increased levels of IL-13Rα2.
▸ IL-13Rα2-bearing cells in UC lamina propria
constitute approximately 60% of the
mononuclear cells present and coexpress IL-13
and CD161.
How might it impact on clinical practice in
the foreseeable future?
▸ The clinical severity of patients with UC might
be assessed by quantitation of cells binding
lyso-sulfatide-loaded tetramer and/or bearing
IL-13Rα2.
▸ UC could be treated by reducing the levels of
lamina propria IL-13Rα2-bearing NKT cell or
IL-13 levels.
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In the present studies we address these unanswered questions.
We establish ﬁrst using CD1d-tetramer binding studies that the
lamina propria of UC patients contains a substantial population
of CD3 T cells whose TCR binds lyso-sulfatide glycolipid, an
endogenous glycolipid antigen previously shown to stimulate
Type II NKT cells.4–7 Further evidence that UC NKT cells have
TCRs responsive to sulfatide glycolipid came from studies
showing that this antigen stimulates UC lamina propria cells to
secrete IL-13, and to exhibit enhanced epithelial cell cytotox-
icity. Additionally, we show that sulfatide glycolipid antigen
upregulates NKT cell expression of IL-13Rα2, a high-afﬁnity
IL-13 receptor. Finally, we performed extensive studies of the
phenotype of IL-13Rα2-expressing cells, and using this receptor
as a UC NKT cell marker obtained evidence that NKT cells
make up the majority of cells in the UC lamina propria.
MATERIALS AND METHODS
Patient population
Sixty-four patients (pts) admitted to the Cleveland Clinic
(Cleveland, OH) and the NIH Clinical Center contributed colonic
tissue for these studies. These included 31 UC patients with severe
(26 pts) or moderate (5 pts) disease based on the criteria of
Truelove8 and 21 Crohn’s disease patients with severe (18 pts) or
moderate (3 pts) disease based on the criteria of De Dombal9; all
CD patients had colonic involvement only. Patients with adenocar-
cinoma of the colon (n=12) who contributed the normal margin
zone tissue served as controls. The institutional review boards of
the Cleveland Clinic and the National Institute of Allergy and
Infectious Disease, NIH approved collection of surgical specimens.
Informed consent was obtained from all patients.
Preparation of lamina propria mononuclear cells
Lamina propria mononuclear cells (LPMC) were isolated from
freshly obtained surgical specimens from IBD and non-IBD
control patients as previously described.1 For determination of
ex vivo LPMC cytokine production for IL-13, IFN-γ or IL-4,
LPMC were cultured as previously described1 and as deter-
mined in the online supplementary information.
Real-time PCR
Aliquots of LPMC cells obtained from UC, Crohn’s disease and
control individuals were subjected to RNA extraction using
RNeasy tissue kit (Qiagen Valencia Calif ). A total of 100 ng
template RNA was reversed transcribed with Superscript III
RT-PCR kit (Invitrogen, Carlsbad, California). Primer sequences
for IL-13Rα2, IL-13Rα1, CD161, IL-17A and β-actin are as
listed in online supplementary information.
Protein synthesis inhibition assay
A protein synthesis inhibition assay (as described in online sup-
plemental information) was employed to secondarily assay the
surface expression of IL-13Rα2 on LPMC.10 11
Quantum dot immunostaining of LPMC cells
LPMC cells from UC, CD or control individuals were subjected
to in situ histochemical (IHC) staining using a modiﬁed
quantum dot (Q dot) technique as described in online supple-
mentary information.12
Detection of sulfatide glycolipid-loaded
CD1d-tetramer-binding cells
LPMC were stained with unloaded or loaded tetramer, and
underwent ﬂow cytometric and Q-dot staining analysis as indi-
cated in online supplemental information.
Statistical analysis
Statistical differences were assessed using the Student t test and
Bonferroni correction analysis for multiple parameter correl-
ation. All values of p<0.05 were considered statistically
signiﬁcant.
RESULTS
LPMC of UC is populated by NKT cells that bind
lyso-sulfatide-loaded tetramer
As noted above, inﬂamed UC tissue contains Type II (non-
invariant) NKT cells that do not express Vα24 and do not
respond to α-galactosylceramide.1 We therefore considered the
possibility that these cells have TCRs that recognise one or
more of the sulfatide family of glycolipids, that is, self-
glycolipids that have recently been shown to stimulate Type II
NKT cells.4–7 To examine this possibility, we generated sulfatide-
loaded CD1d tetramers using individual sulfatide isoforms
previously shown to have NKT cell stimulatory activity:14 15
ceramide-galactoside-3-sulfate (ceramide sulfatide) and
sphingosine-1-galactoside-3-sulfate (lyso-sulfatide). We then
incubated LPMC puriﬁed from UC and control lamina propria
tissue with sulfatide-loaded tetramers, and subjected the cells to
a highly sensitive Q-dot-staining technique that maximises
detection of stained cells in dispersed cell populations (see
Methods and online supplementary information).12 Finally, we
enumerated tetramer-positive cells by blinded counting of
stained cells in dispersed cell populations using both visual
observation and computer analysis; alternatively, we enumerated
tetramer-positive cells by ﬂow cytometry. We found that LPMCs
from UC patients contained a population of lyso-sulfatide
tetramer-positive cells that was not only approximately fourfold
to ﬁvefold greater than in LPMCs from Crohn’s disease or
normal control patients (ﬁgure 1A), but also characterised by far
greater tetramer staining intensity (ﬁgure 1B). Indeed, while the
low-level staining characterising Crohn’s disease and normal
control LPMC was observed by examination of slides by light
microscopy, it was too faint for photographic display. Further
studies indicated that these lyso-sulfatide positive cells in UC
LPMC were indeed T cells, as they were concomitantly positive
for the T cell marker CD3 (ﬁgure 1C). Similar results were
obtained when tetramer staining was analysed by ﬂow cytome-
try (ﬁgure 1D). It should be noted that cells in UC LPMC did
not exhibit signiﬁcant binding of ceramide sulfatide-loaded tet-
ramers (see online supplementary ﬁgure 1), possibly reﬂecting
the fact that they have TCRs that bind this form of sulfatide
with an afﬁnity below that necessary to detect tetramer binding
using the technique presently available.
Sulfatide glycolipids induce UC NKT cell IL-13 production
In a second approach to evaluating if UC NKT cells recognise a
sulfatide glycolipid, we determined if the latter stimulates NKT
cells in UC LPMC to produce IL-13, a cytokine previously
shown to be produced by UC NKT cells.1 In this case, we stimu-
lated the cells with lyso-sulfatide and ceramide sulfatide as well
as an additional sulfatide family member also shown to stimulate
NKT cells, N-tetra-sulfatide (N-tetracosanoyl-sphingosyl-β-D-
galactoside-3-sulfate).14 15 We found that lyso-sulfatide and cer-
amide sulfatide stimulated UC LPMC to produce IL-13 (74 pg
and 31 pg/mL, respectively), whereas, N-tetra-sulfatide had no
stimulatory effect (ﬁgure 2A).
Important negative results obtained in these studies included
the fact that none of the sulfatides induced increased secretion of
IFN-γ (ﬁgure 2: the mean IFN-γ secretion of 32.7 pg/mL by cells
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stimulated with lyso-sulfatide was not different than that of
unstimulated cells. Additionally, LPMC from Crohn’s disease
patients were not stimulated by any of the sulfatides tested to
produce measurable amounts of IL-13 or IFN-γ (ﬁgure 2A and
B: mean production of 9 and 210 pg/mL, respectively, by cells sti-
mulated with lyso-sulfatide similar to that of unstimulated cells.
Finally, none of the sulfatides induced either UC or CD LPMC to
produce measurable amounts of IL-4 (data not shown).
In another series of studies involving additional UC patients,
we determined whether induction of IL-13 by lyso-sulfatide was
inhibited by the presence of anti-CD1d. We found that addition
of optimal amounts of anti-CD1d to cultures of LPMC led to a
statistically signiﬁcant decrease in IL-13 secretion (range 41–
63%; p<0.04). By contrast, addition of anti-MHC class II had
no effect on the level of lyso-sulfatide-induced IL-13 secretion
(data not shown). These results indicate that lyso-sulfatide
stimulation was acting, at least in part, via CD1d-mediate sulfa-
tide presentation to NKT cells.
Lyso-sulfatide stimulation of UC LPMC enhances CD161 T
cell cytotoxicity of epithelial cells
In other studies also addressing the capacity of UC LPMC to
recognise and respond to a sulfatide glycolipid, we determined
whether the most active sulfatide in the IL-13 secretion study,
Figure 1 (A) Puriﬁed LPMCs were isolated from UC (n=6), CD (n=3) and control patient populations (n=3), and subjected to Q-dot staining
analysis to detect binding of lyso-sulfatide tetramer. Percent expression of lyso-sulfatide tetramer binding is shown. Percent expression represents
lyso-sulfatide binding for each patient sample minus expression of binding for unloaded tetramer of each patient sample. All datasets from each
patient were performed in triplicate. For staining percentage comparison, p<0.01 ulcerative colitis versus Crohn’s disease, or normal controls and
p<0.0001 for staining intensity with no statistical difference for Crohn’s disease versus normal controls for percentage staining (p>0.9), or staining
intensity (p>0.4) (B) Puriﬁed LPMCs were isolated from UC (n=6), CD disease (n=3) and control patients (n=3) and subjected to Q-dot staining to
detect binding of lyso-sulfatide tetramer. One representative staining experiment is shown. (C) Puriﬁed LPMCs were isolated from UC patient
population (n=2), and subjected to Q-dot staining to detect binding of lyso-sulfatide tetramer and CD3, range 52–58% Lyso-sulfatide+/CD3. (D)
Puriﬁed LPMCs were isolated from UC (n=6), CD (n=3) and control patient populations (n=3) were subjected to Q-dot staining for ﬂow cytometry
analysis to detect binding of lyso-sulfatide tetramer. Mean MFI for normal control 886, Crohn’s disease 726, Ulcerative colitis 2076.
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lyso-sulfatide, induces cytotoxicity of LPS-stimulated HT-29 epi-
thelial cells, that is, epithelial cells expressing surface CD1d (see
Methods). In this case, we evaluated the cytotoxic potential of
puriﬁed CD4 CD161 LP cells rather than whole LPMCs, since,
in a prior study, we have shown that this cell subpopulation
mediates epithelial cell cytotoxicity.1 We found that CD4
CD161 LP cells obtained from lamina propria of UC patients
exhibited considerable baseline cytotoxic activity (mean 12.4%)
in the absence of any added sulfatide (ﬁgure 2C). It is likely that
this was due to the fact that normal epithelial cells display sulfa-
tide glycolipids on their cell surface and, therefore, can stimulate
cytotoxic activity by CD161 T cells in the absence of added sul-
fatide glycolipid16; thus, the true baseline may be better repre-
sented by that exhibited by puriﬁed CD4 CD161 LP cells
obtained from CD patients (2.9%) which do not respond to the
sulfatide glycolipids studied here (data not shown). Thus, add-
ition of lyso-sulfatide led to a signiﬁcant further enhancement
of cytotoxicity when compared to the UC cell baseline.
Lyso-sulfatide stimulation of UC LPMC induces upregulation
of IL-13Rα2
In previous studies, we observed that IL-13 augmented UC
NKT cell cytotoxicity of an epithelial target cells.1 This implied
that UC NKT cells bear an IL-13 receptor and prompted us to
determine if lyso-sulfatide stimulation of UC LPMC induces
such receptor expression. In initial studies, we assessed
IL-13Rα1 expression in LPMCs employing a Q-dot-based in
situ histochemical staining technique. We found that IL-13Rα1
was barely detectable in UC LPMC (+1 low-staining intensity)
and stained cells comprised a relatively low fraction of UC
LPMC that was not augmented by lyso-sulfatide stimulation (34
±5.3% prelyso-sulfatide, and 35±4.1% postlyso-sulfatide stimu-
lation) (ﬁgure 3A). This result was corroborated by the fact that
UC LPMC displayed no detectable IL-13Rα1 receptor mRNA
expression prelyso-sulfatide and postlyso-sulfatide stimulation
(data not shown).
A very different result, however, was found applying the same
approaches to assessment of UC LPMC IL-13Rα2 expression. In
this case, the LPMCs displayed a much higher baseline percent-
age of detected stained cells bearing IL-13Rα2 than LPMCs
from CD or control patients, as well as greatly increased levels
of IL-13Rα2 mRNA (ﬁgure 3B and see online supplementary
ﬁgure 2). Additionally, quantitative assessment of staining data
using both computer analysis and visual observation disclosed
that the percentage of IL-13Rα2+ cells in UC LPMC popula-
tions increased from a baseline value of 61±5.6% to a
lyso-sulfatide-stimulated value of 79±7.8% (p<0.05) (ﬁgure
3C); thus, lyso-sulfatide stimulation of LPMC induced a sub-
stantial increase in the number of cells bearing this receptor,
and augmented the intensity of IL-13Rα2 staining on individual
cells.
In complementary studies to verify the above effect of lyso-
sulfatide on UC LPMC IL-13Rα2 expression, we measured
changes in lyso-sulfatide-induced IL-13Rα2 expression on indi-
vidual cells in a cell lysis assay dependent on targeting cell surface
IL-13Rα2 with increasing concentrations of IL-13-pseudomonas-
exotoxin (IL-13-PE), an agent that reacts speciﬁcally with and
then induces cytotoxicity of IL-13Rα2-bearing cells. In this assay,
cell lysis by IL-13-PE pre-exposure and postexposure of cells to
lyso-sulfatide is assessed by changes in the capacity of unlysed
cells to incorporate leucine (a measure of protein synthesis); add-
itionally, since cell lysis by IL-13-PE is dependent on the density
of IL-13Rα2 expression on individual cells, the rate of decrease
in leucine incorporation with increasing IL-13PE concentration is
a measure of lyso-sulfatide-induced IL-13Rα2 expression in indi-
vidual cells.10 11
These cell-lysis studies showed that the rate of leucine incorp-
oration decrease by UC LPMC was enhanced postlyso-sulfatide
exposure compared to prelyso-sulfatide exposure (see online
Figure 2 Cytokine secretion by UC (upper panels of A & B) and CD (lower panels of A & B) LPMCs. (A) IL-13 and (B) IFN-γ secretion obtained
from inﬂamed UC (n=3) and inﬂamed CD (n=3) tissues induced by either indicated sulfatide glycolipids or CD3/CD28 as previously indicated.4–7
Error bars represent 1 SD. *p≤0.05 Ceramide sulfatide versus unstim, **p≤0.05 Lyso-sulfatide vs unstim, NS; Not statistically signiﬁcant (C)
Cytotoxicity of CD161 T cells. HT-29 epithelial cells were pre-stimulated with LPS to induce increased expression of CD1d (data not shown). Puriﬁed
UC lamina propria CD4 CD161 T cells were cultured with target HT-29 cells at a ratio of 10 : 1 and in the presence or absence of lyso-sulfatide and/
or IL-13, and the percentage of cytotoxicity was measured (n=3). Error bars represent 1SD. *p≤0.05, N.S.; Not statistically signiﬁcant p≥0.1.
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supplementary ﬁgure 3). Thus, while approximately 10 ng/mL
of IL-13-PE was required to achieve a 50% decrease in protein
synthesis in cells, prelyso-sulfatide exposure, only 1 ng/mL of
IL-13-PE was necessary for the same decrease postlyso-sulfatide
exposure. These results are consistent with those obtained with
the Q-dot staining studies in showing that lyso-sulfatide induces
an increased number of IL-13Rα2-expressing cells; however,
they go a step further in showing that lyso-sulfatide also induces
an increased concentration of IL-13Rα2 on individual cells. Of
note, no change in leucine incorporation was observed in
studies of CD and normal control LP cells indicating that these
cells exhibit little, if any, IL-13Rα2 expression.
Expression of IL-13Rα2 on lamina propria cells in patients
with ulcerative colitis
Given the above relationship of IL-13Rα2+ cells to lyso-
sulfatide stimulation, we next determined the expression of this
receptor on lyso-sultatide-loaded tetramer-positive UC LPMCs
Figure 3 UC LPMC IL-13Rα1 and IL-13Rα2 expression. (A) Left panel: UC LPMC cells stimulated in vitro with lyso-sulfatide and subjected to Q-dot
staining for IL-13Rα1. One representative Q-dot staining of UC LPMC depicting IL-13Rα1 expression, pretreatment (top left panel) and
post-treatment with lyso-sulfatide (bottom left panel) is shown. Right panel: Glioblastoma cell line (U251) which has a high expression of IL-13Rα1
served as a positive control. (B) Puriﬁed LPMC were obtained from UC, CD and control patient populations and subjected to Q-dot staining FACS
analysis for IL-13Rα2. One representative histogram from each group depicting % expression of IL-13Rα2 is shown. Range of expression for each
group: UC 48–65% (n=5), CD 4.0–8.3% (n=3), controls 1.8–4.0% (n=3). (C) UC LPMC cells stimulated in vitro with lyso-sulfatide and subjected to
Q-dot staining for IL-13Rα2. One representative Q-dot staining of UC LPMC depicting IL-13Rα2 expressing cells is shown (n=3).
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using dual Q-dot staining. We found that, indeed, virtually all
tetramer-positive cells coexpressed IL-13Rα2 (ﬁgure 4), whereas
by contrast, these dual-staining cells were absent in CD LPMC
populations. This result suggested that IL-13Rα2 could be used
as a marker of NKT cells in UC lamina propria and prompted
us to conduct studies of the phenotype and frequency of
IL-13Rα2-positive cells in the UC lamina propria. In initial
semiquantitative staining studies of LPMC, we found that
IL-13Rα2-bearing cells were numerous in these populations and
frequently coexpress IL-13 and CD161 (ﬁgure 5A). Moreover,
the IL-13Rα2-bearing cells did not coexpress IL-4 or IFN-γ
(ﬁgure 5B), and did not coexpress CD14, the latter ruling out
expression by inﬂammatory macrophages (data not shown).
In subsequent and more quantitative studies, we subjected
LPMC to staining studies in which cell counts were established
by blinded computer analysis and visual assessment of stained
cells. The results, depicted in table 1, show that IL-13Rα2+ cells
comprised 70.3±9.4% of total dispersed lamina propria cells, a
percentage not signiﬁcantly different from that of CD161 cells,
67±7.6%; (p>0.5) moreover, these markers were generally
present on the same cells since IL-13Rα2+/CD161 double-
positive cells comprised 58.7±9.2% of the total LPMC
Figure 4 Puriﬁed LPMCs isolated
from ulcerative colitis patients (n=5)
were subjected to Q-dot staining to
detect IL-13Rα2 expression and
binding of lyso-sulfatide tetramer.
Expression of cells demonstrating dual
IL-13Rα2 staining and binding of
lyso-sulfatide tetramer was 36±6%
(with a staining intensity of +3) while
that of Crohn’s disease (n=3) was 4
±1% (data not shown) with a staining
intensity of < +1) (p<0.008). Dataset
from each patient was performed in
triplicate.
Figure 5 (A) Q-dot staining of UC LPMC reveals CD161 cells exhibit increased expression of IL-13Rα2 and IL-13. Puriﬁed LPMC obtained from
inﬂamed UC tissue were subjected to Q-dot staining and analysed for expression of IL-13Rα2, IL-13, CD161 and for coexpression of these markers.
One representative Q-dot staining of UC LPMC is shown (n=7). (B) Puriﬁed LPMC obtained from inﬂamed UC tissue were subjected to Q-dot
staining and analysed for expression of IL-13Rα2, IL-4, IFN-γ and for coexpression of these markers. Q-dot study of UC LPMC shown is
representative of seven such studies of individual patients. One representative Q-dot staining of UC LPMC is shown (n=7).
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dispersed cells (p>0.07). Additionally, IL-13+ cells comprised
65.7±5.9% of the total cells, again not signiﬁcantly different
from the percentage of IL-13Rα2+ or CD161 cells (p>0.3,
p>0.5 respectively) and most of these cells also bore IL-13Rα2
since the percentage of IL-13Rα2+/IL-13+ cells was 58.4
±10.7%, a percentage equivalent to that of IL-13-bearing cells
(p>0.1) allowing for the fact that the detection of double posi-
tive cells was not as efﬁcient as the detection of single positive
cells. Finally, about 45–50% of the LPMC in UC were CD4 T
cells, most of which were present in the IL-13Rα2+CD161
population; additionally, in the one patient studied, 6% of
LPMC were lightly stained CD8 T cells. Overall, these studies
provide deﬁnitive evidence that a large proportion of UC
lamina propria cells bear markers associated with NKT cells,
IL-13Rα2 and CD161, most, if not all of which secrete IL-13.
Concomitant studies of Crohn’s disease LPMC disclosed that
high-level expression of IL-13Rα2 and CD161 was a unique
feature of UC cells. Thus, both IL-13Rα2 and CD161 was
detected on only 5–10% of cells, and the intensity of staining of
these positive cells was quite low (see online supplementary
ﬁgure 4). Likewise, only 6–16% of the cells exhibited IL-13
staining, and the intensity of staining of these positive cells was
low. Thus, UC LPMCs contained a signiﬁcantly higher percent-
age of cells than Crohn’s disease or control LPMCs of cells posi-
tive for IL-13, IL-13Rα2, CD161, IL-13Rα2/CD161 and IL-13/
IL-13Rα2 (p<0.007 Bonferroni correction for multiple param-
eter analysis), whereas CD and control LPMCs exhibited no dif-
ference in these parameters (p>0.1). Additionally, while UC
lamina propria cells revealed only low-level intensity and insig-
niﬁcant staining for IL-4 and IFN-γ, CD lamina propria cell
populations exhibited strong IFN-γ staining and some low-
intensity IL-4 staining. With regard to the latter, it should be
noted the IL-4 staining was not accompanied by detectable IL-4
secretion either in the present studies or in previous studies.17
IL-17A mRNA production in UC LPMCs was slightly greater
than that of normal control, but decreased in comparison with
that of CD LPMC (data not shown). Finally, whereas a substan-
tial subpopulation of UC LPMC CD161 cells also expressed
IL-5, virtually little of these cells expressed IL-17 (see online
supplementary ﬁgure 5).
Secretion of IL-13 by UC LP cells following treatment
with IL-13-PE
Taking a more functional approach to relating IL-13Rα2 expres-
sion to NKT cells in UC, we measured IL-13 production by
LPMC before and after culture with IL-13-PE using the latter to
selectively eliminate IL-13Rα2-bearing cells. We found that
prior exposure of LPMC from UC patients to IL-13-PE led to a
signiﬁcant decrease in the amount of IL-13Rα2+ cells (see
online supplementary ﬁgure 6A). Additionally, LPMC from UC
patients pre-exposed to IL-13-PE, and then activated with
anti-CD3/anti-CD28 in vitro caused a mean 68% reduction in
IL-13 secretion but no change in IFN-γ secretion (see online
supplementary ﬁgure 6B and data not shown, respectively). This
reduction was similar in magnitude to the reduction in the
number of IL-13Rα2+ cells, suggesting that most, if not all, of
IL-13 was, in fact, being produced by receptor-positive cells.
Similar results were obtained when cytotoxicity was used as a
read-out rather than IL-13 production in that again, the reduc-
tion in cytotoxicity was similar to the reduction in the number
of CD161 cells (see online supplementary ﬁgure 6C and D).
While these results require veriﬁcation with studies of additional
patients, they provide additional evidence that IL-13Rα2+ is a
marker of LP NKT cells in UC patients.
DISCUSSION
In previous studies, we obtained several kinds of evidence sug-
gesting that UC was associated with the presence of lamina
propria non-invariant (Type II) NKT cells. Most importantly, we
showed that in parallel with invariant NKT cells in the lamina
propria of mice with oxazolone colitis (oxa-colitis) that produce
IL-13 upon stimulation with α-GalCer, non-invariant CD161
cells in the UC lamina propria produce IL-13 when stimulated
with CD1d-expressing APCs.1 2 Additionally, we showed that
the UC lamina propria contains T cells that are cytotoxic for
LPS-stimulated epithelial cells, and that this cytotoxicity is aug-
mented by the presence of IL-13.1 In the present study, we
expand on these ﬁndings by showing that a substantial popula-
tion of LPMC from UC patients bind sulfatide glycolipid-loaded
CD1d tetramer and, thus, bear TCRs that react to a glycolipid
previously shown to interact with non-invariant NKT cells.4–7
Additionally, we show that UC LPMC can be stimulated by sul-
fatide glycolipid to produce IL-13 and to manifest cytotoxicity
for LPS-stimulated epithelial cells that is substantially inhibited
by the presence of anti-CD1d antibody. These new data not
only provide strong new support for the idea that non-invariant
NKT cells do, in fact, populate the LP of UC patients but may
establish the identity of the TCR-reactive antigen capable of
stimulating these cells.
Staining of UC lamina propria cells with labelled lyso-
sulfatide-loaded tetramers indicated that a very substantial frac-
tion of these cell, approximately 36%, were, in fact, Type II
NKT cells. However, this could be an underestimate of the per-
centage of NKT cells in UC lamina propria because lyso-
sulfatide might bind to the TCR of UC NKT cells with an afﬁn-
ity that is suboptimal when compared to that of an as-yet
Table 1 Analysis of lamina propria cells by Q-dot staining
Mean staining intensity
Mean±SD (% positive cells) (range) IL-13Rα2 CD161 IL-13 IL-4 IFN-γ IL-13Rα2+CD161 IL-13Rα2+IL-13
Ulcerative colitis (n=7) 3.3+
70.3±9.4a
(58–84)
3.4+
67±7.6b
(54–78)
3+
65.7±5.9c
(58–74)
1+
8±1.9
(6–10)
1+
7.7±1.8
(6–10)
3+
58.7±9.2d
(45–68)
2.9+
58.4±10.7e
(39–70)
Crohn’s disease (n=6) <1+
9.2±3.1
(6–14)
<1+
7.8±2.0
(6–10)
<1+
9.5±4.0
(6–16)
2+
38±5.0
(30–44)
2.5+
56.5±6.1
(51–64)
<1+
5.5±1.5
(4–8)
<1+
6±1.4
(4–8)
Normal (n=4) <<1+
7±2.2
(5–10)
<<1+
6.3±1.3
(5–8)
<<1+
6.3±1.3
(5–8)
1.25+
15±2.6
(4–28)
<<1+
6±1.4
(5–8)
<<1+to 1+
3.3±1
(2–4)
<<1+
5.8±1.7
(4–8)
Statistical analysis: a vs b: p≥0.5; a vs c: p≥0.3; b vs c: p≥0.5; b vs d: p≥0.07; c vs e: p≥0.1.
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unidentiﬁed endogenous stimulatory sulfatide actually present in
the UC lamina propria. As an alternative approach to NKT cell
quantitation in UC, we explored the possibility that IL-13Rα2
present on LPMCs could be a surrogate marker of the NKT cell
subpopulation. Two observations suggested that was likely to be
the case. First, stimulation of UC LPMC with sulfatide upregu-
lated the number of cells bearing IL-13Rα2, and also increased
the level of expression of this receptor on individual cells.
Second, dual staining of LPMC to identify tetramer-positive
cells and IL-13Rα2-positive cells revealed that virtually all the
tetramer-positive cells were also IL-13Rα2-positive.
In further studies along these lines, we evaluated the number
and phenotype of IL-13Rα2-bearing cells in UC lamina propria
using a sensitive and unbiased in situ staining technique coupled
with ﬂow cytometry. This revealed that the majority of UC
LPMCs bear IL-13Rα2, whereas only a small percentage of
Crohn’s disease, or control LPMCs, bear this receptor, and then
at a low expression level. Additionally, the receptor-bearing cells
also bear the NKT cell marker, CD161, and most are
IL-13-producing cells. These latter ﬁndings provide additional
support for the view that IL-13Rα2 is a valid marker of NKT
cells in UC since CD161 is a known marker of NKT cells and
IL-13 production, as noted previously in studies of oxazolone
colitis and UC patients.1 2 Additional support for the idea that
IL-13Rα2 is an NKT cell marker in UC LP came from studies
showing that IL-13-PE-mediated depletion of UC lamina
propria cells led to a greatly reduced level of IL-13 production
and cytotoxic activity, both of which were proportional to the
extent of depletion. Overall, these phenotypic studies of lamina
propria cell populations provide strong evidence that
IL-13Rα2+ IL-13+CD161 T cells make up the majority of cells
in the inﬂamed UC mucosa.
The fact that UC NKT cells express IL-13Rα2, but little or no
IL-13Rα1, was a somewhat unexpected characteristic of these
cells although it was presaged by a previous study showing that
this receptor is expressed in the lamina propria of oxazolone-
colitis in western blot studies that did not identify the cellular
origin of the IL-13Rα2.18 19 Of interest, in this previous study,
down-regulation of IL-13Rα2 expression was shown to be asso-
ciated with a reduced level of colitis. This correlates with the
fact that sulfatide glycolipid induces NKT cell IL-13 production,
and the latter, in turn, stimulates NKT cell cytotoxic function.
The ﬁnding that UC is characterised by the presence of a
lamina propria self-antigen (sulfatide)-responsive Type II NKT
cell population invites a re-examination of the underlying
pathogenesis of this disease. One important possibility that
needs to be considered on the basis of this new information is
that the key pathologic event occurring in UC consists of an
abnormality in the way epithelial cells process and display a self-
glycolipid (sulfatide) antigens perhaps in response to a ‘stress’
signal from the luminal microbiota. Support for this possibility
comes from a recent report that an epithelial cell-speciﬁc muta-
tion of XBP1, an intracellular protein critical to the initiation of
the endoplasmic reticulum stress response of secretory cells, is
associated with being hyper-responsive to an innate ligand and
results in spontaneous intestinal inﬂammation or increased sus-
ceptibility to induced colitis.20 On this basis, one might specu-
late that while a proximal cause of UC is an NKT cell-mediated
autoimmune-like response, the more basic cause of this disease
lies in a defect in the way epithelial cells respond to the
endogenous microbiome. This latter possibility ﬁnds support in
a recent study by Olszak et al, which showed that neonatal
germ-free mice exhibit increased LPs NKT cell inﬁltration and
heightened oxazolone colitis, a mouse model of UC.21
Finally, the ﬁndings reported here showing that UC is charac-
terised by the presence of NKT cells bearing IL-13Rα2 suggest
that this receptor could be used as a marker for UC and at the
same time, would provide insight into disease severity.
Additionally, since NKT cells which produce IL-13 may be the
main effector cell driving UC inﬂammation, this receptor could
also be targeted by potential UC therapeutic agents. The latter
presently being investigated with therapeutic agents targeting
IL-13.
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